535 related articles for article (PubMed ID: 27336891)
1. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
Shi M; Chen X; Ye K; Yao Y; Li Y
Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
3. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
Tartey S; Takeuchi O
Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
Ohadian Moghadam S; Nowroozi MR
Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors in breast cancer immunity and immunotherapy.
Zhou J; Zhang L; Liu S; DeRubeis D; Zhang D
Front Immunol; 2024; 15():1418025. PubMed ID: 38903515
[TBL] [Abstract][Full Text] [Related]
7. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
Li K; Qu S; Chen X; Wu Q; Shi M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
[TBL] [Abstract][Full Text] [Related]
8. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.
Chen YH; Wu KH; Wu HP
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732254
[TBL] [Abstract][Full Text] [Related]
11. Targeting Toll like Receptors in Cancer: Role of TLR Natural and Synthetic Modulators.
Narayanankutty A; Sasidharan A; Job JT
Curr Pharm Des; 2020; 26(39):5040-5053. PubMed ID: 32693759
[TBL] [Abstract][Full Text] [Related]
12. [Responses with participation of toll-like receptors in protective immunity and in pathologic states].
Skivka LM; Pozur VV
Ukr Biokhim Zh (1999); 2008; 80(3):5-20. PubMed ID: 18959023
[TBL] [Abstract][Full Text] [Related]
13. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals.
Vidya MK; Kumar VG; Sejian V; Bagath M; Krishnan G; Bhatta R
Int Rev Immunol; 2018 Jan; 37(1):20-36. PubMed ID: 29028369
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors, inflammation and cancer.
Tsan MF
Semin Cancer Biol; 2006 Feb; 16(1):32-7. PubMed ID: 16153858
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
Noh JY; Yoon SR; Kim TD; Choi I; Jung H
J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
[TBL] [Abstract][Full Text] [Related]
17. [Progress of research on TLRs-mediated signaling pathway].
Chang XT; Nian XF; Wang ZH
Sheng Li Ke Xue Jin Zhan; 2011 Oct; 42(5):340-6. PubMed ID: 22242400
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
[TBL] [Abstract][Full Text] [Related]
19. TLR signaling by tumor and immune cells: a double-edged sword.
Huang B; Zhao J; Unkeless JC; Feng ZH; Xiong H
Oncogene; 2008 Jan; 27(2):218-24. PubMed ID: 18176603
[TBL] [Abstract][Full Text] [Related]
20. Innate immunity and cancer therapy.
Maruyama K; Selmani Z; Ishii H; Yamaguchi K
Int Immunopharmacol; 2011 Mar; 11(3):350-7. PubMed ID: 20955832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
